Detalhe da pesquisa
1.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422028
2.
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.
Future Oncol
; 10(13): 2081-96, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25396779
3.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
J Clin Oncol
; 35(35): 3924-3933, 2017 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023213
4.
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Clin Lung Cancer
; 15(2): 166-70, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24418693